Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker for viral pneumonia and application of marker

A viral pneumonia, marker technology, applied in antiviral agents, medical preparations containing active ingredients, disease diagnosis, etc.

Pending Publication Date: 2021-09-10
GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there is no relevant report on the application of cyclooxygenase II inhibitors, especially celecoxib, in the treatment of coronavirus pneumonia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for viral pneumonia and application of marker
  • Marker for viral pneumonia and application of marker
  • Marker for viral pneumonia and application of marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1 Preliminary clinical trial of celecoxib

[0044] In this example, on the basis of conventional treatment following the guidelines, in cooperation with the Guangzhou Eighth People's Hospital, a clinical study of the type II cyclooxygenase inhibitor celecoxib in the treatment of new coronary pneumonia was carried out. Cloth for clinical research, oral administration for 10-14 days, twice a day, 200 mg each time, the specific cases are as follows:

[0045] The first batch of 8 cases were enrolled in the test group (4 cases of severe disease, 4 cases of common type), and 7 cases of the control group (7 cases of common type). Follow-up evaluations were conducted on the 4th and 10th days of treatment and found that the condition had improved. All of them were improved, and there was no serious condition; the condition of the control group was aggravated, unchanged and improved, respectively 42%, 14% and 42%. The curative effect of the experimental group was signifi...

Embodiment 2

[0046] Embodiment 2 celecoxib expanded clinical trial

[0047] In this example, in order to further verify the clinical research of the type II cyclooxygenase inhibitor celecoxib in the treatment of new coronary pneumonia, further increase the number of enrolled groups, the specific cases are as follows:

[0048] As of February 23, 2020, 31 cases (6 cases of severe disease and 25 cases of common type) were formally enrolled in the trial group. The specific medication and results are shown in Table 1 below:

[0049] Table 1

[0050]

[0051] It can be seen from Table 1 that among all the 38 cases including the test group and the control group, 84.2% (32 / 38) of the patients were admitted with mild disease (mild or common CT imaging manifestations), and 15.7% ( 6 / 38) patients were seriously ill (severe) when they were admitted to the hospital, after treatment (1) 31 / 31 cases improved (100% improvement rate); (2) 31 / 31 cases of virus turned negative (negative rate 100%) ; (3)...

Embodiment 3

[0052] Clinical diagnosis of embodiment 3 PGE2

[0053] In this example, in order to further verify the clinical research of the type II cyclooxygenase inhibitor celecoxib in the treatment of new coronary pneumonia, and further analyze the correlation between PGE2 and changes in the condition of new coronary pneumonia, this example tracks and detects patients with new coronary pneumonia every day The level of PGE2 in the urine, and compared with the CT results, the results are as follows figure 1 shown.

[0054] From figure 1 It can be seen that there are three patterns of PGE2 level changes between two adjacent CT detections: 1) figure 1 In (A) there is a climbing peak exceeding 1000ng / ml; 2) figure 1 (C) falls from a peak value exceeding 1000 ng / ml; 3) figure 1 In (E), the small amplitude vibration is lower than the baseline of 100ng / ml; corresponding to the analysis of two adjacent CT results, there are also three corresponding disease regressions, such as figure 1 (B)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine application, in particular to a marker for viral pneumonia and application of the marker. The marker for viral pneumonia is prostaglandin E2 and / or prostaglandin M. According to the invention, prostaglandin E2 and / or prostaglandin M are / is taken as the marker of viral pneumonia, and an epoxidase II inhibitor is used, so that prostaglandin can be effectively and rapidly reduced, the development of ordinary and severe diseases can be reversed, the occurrence of critical diseases can be blocked, and the conversion of viruses into negative, pneumonia absorption and health recovery can be promoted. Under the condition that the curative effect is further confirmed, the clinical application range of the medicine is expanded, the treatment method is incorporated into a clinical diagnosis and treatment scheme, and a new strategy and a diagnosis and treatment method are provided for comprehensive treatment of novel coronavirus pneumonia.

Description

technical field [0001] The invention relates to the field of drug application, in particular to a marker of viral pneumonia and its application. Background technique [0002] Coronaviruses are a large family of viruses known to cause colds as well as more serious illnesses such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). Common signs after a person is infected with a coronavirus include respiratory symptoms, fever, cough, shortness of breath, and dyspnea. In more severe cases, infection can lead to pneumonia, severe acute respiratory syndrome, kidney failure, and even death. Currently, there is no specific treatment for the disease caused by the novel coronavirus. [0003] Celecoxib (Celecoxib), has a unique mechanism of action that specifically inhibits COX-2, the chemical name is 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1 hydrogen-1 -pyrazol-1-yl]benzenesulfonamide, its molecular formula is C17H14F3N3O2S, its molecular weigh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/88A61K45/00A61K31/635A61P11/00A61P31/14A61P31/16
CPCG01N33/88A61K45/00A61K31/635A61P11/00A61P31/14A61P31/16G01N2800/12
Inventor 李尹雄陈彦游凯谭圣林
Owner GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com